|

Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer

RECRUITINGSponsored by AstraZeneca
Actively Recruiting
SponsorAstraZeneca
Started2025-10-25
Est. completion2027-05-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06827132

Summary

A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:Sample from adult patients (≥ 18 years) with suspected non-small cell lung cancer or invasive breast cancer or ductal carcinoma in situ.

\-

Exclusion Criteria:

* Samples with the inadequate technical quality of slides (pre-analytics quality) or images, e.g., broken slides, large out-of-focus areas, slides with fixation artefacts.

  * Samples from cases that were included in the training or technical validation.
  * Sample taken by fine needle aspiration.
  * Sample sent for cytological evaluation.

Conditions3

Breast CancerCancerLung Cancer

Browse More Trials

Cancer trialsBreast Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.